Michael McPhee, MD
Surgical Oncology · Altamonte Springs, FLNPI 1285685495
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Kerecis Limited accounts for 94.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $9,091, more than ten times the $105 reported in 2019.
Across 61 payments — averaging $193.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kerecis Limited$11K
- Organogenesis Inc.$283
- Solventum Corporation$187
- Regeneron Healthcare Solutions, Inc.$57
- Vanda Pharmaceuticals Inc.$34
- Iovance Biotherapeutics, Inc.$33
- plus $106 from 7 others
What the payments were for
- Consulting fees$4554%
- Speaking & faculty fees$6,56356%
- Travel & lodging$3,04426%
- Food & beverage$1,73815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kerecis Limited | 28 | $11,100 |
| Organogenesis Inc. | 15 | $283 |
| Solventum Corporation | 6 | $187 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Iovance Biotherapeutics, Inc. | 2 | $33 |
| Genentech USA, Inc. | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Mimedx Group, Inc. | 1 | $15 |
| Almirall LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $12 |
| Merck | 1 | $12 |
| Reprise Biomedical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$32,306
- Kerecis Omega3 Marigen$9,605
- Kerecis GraftGuide$8,077
- Kerecis Omega3 SurgiClose$2,401
How this compares
$11,800 in reported general payments places this provider in the 80th percentile of 133 surgical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 104 | $227 |
| Cephalexin | 25 | $204 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $193 |
| Tramadol Hcl | 61 | $151 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 20 | $88 |
| Methocarbamol | 21 | $74 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Altamonte Springs
- Neha GoelMiami$200K
- Jonathan ZagerTampa$191K
- Horacio AsbunMiami$161K
- Adrian Legaspi SauterHialeah$116K
- Kenneth MeredithSarasota$113K
- Pamela HodulTampa$94K
- Mehran HabibiMiami$73K
- Paul BloomstonFort Myers$68K
- Kristin RojasMiami$57K
- Douglas ReintgenTarpon Springs$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.